Enterprise Europe Network

Nanocapsule compositions for the controlled released of agents of therapeutic interest

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20180223001
Published
27/02/2018
Last update
19/09/2019
Expiration date
31/03/2020

Keywords

Partner keyword: 
Pharmaceutical Products / Drugs
Enzyme Technology
Micro- and Nanotechnology related to Biological sciences
Micro- and Nanotechnology related to Biological sciences
Drug delivery and other equipment
Research and experimental development on biotechnology
EXPRESS YOUR INTEREST

Summary

Summary: 
A Spanish research centre, in collaboration with a Spanish university, works on biomaterials. They have developed a nanocapsule compositions capable of releasing agents of therapeutic interest with a controlled kinetic and a prolonged and sustainable effect over time; reducing the overall administration required. They are looking for license agreement.

Description

Description: 

Fibrosis is a common lesion in different pathological conditions and it is defined by the excessive accumulation of collagen and other extracellular matrix proteins in the connective tissue of different organs where it causes organ dysfunction. Collagen corresponds around of 30% of all proteins in humans, and is the major extracellular protein of different organs such as the skin, cartilage, bones, teeth and cornea.

To prevent this collagen accumulation, proteases are used. Proteases target many substrates, thus inflicting changes in distinct biological processes correlated with fibrosis.

At present, there is still a need to provide protease carriers or vehicles capable of achieving a constant and continuous release of the proteases encapsulated within at therapeutic doses during a sufficient period of time for the treatment of diseases which require a sustained protease administration during treatment periods greater than one week.

A Spanish research team from a of a university hospital and a Spanish university are working on biomedical research in biomaterials and biomedicine. The hospital team works on the rheumatology and dermatology department and the university professor on smart biomaterials for pharmaceutical used. They have developed a nanocapsule compositions capable of releasing agents. The agents, proteases of therapeutic interest, can be released with a controlled kinetic and a prolonged and sustainable effect over time.

The controlled and sustained released solves the above mentioned problems for treatments that last more than one week. It provides sustained release polymeric nanocapsules capable of releasing proteases such as collagenase with a controlled kinetic and a prolonged and sustainable effect over time.

The team is looking for license agreement. They are looking for pharmaceutical or biotechnology companies working on biomolecules, nanocapsules or nanoparticules, to license the patent. It will be desired if they have interest in fibrosis treatment.

Advantages & innovations

Cooperation plus value: 
This novel nanocapsule composition is adaptable to encapsulate and effectively deliver agents of therapeutic interest reducing the overall administration required. These capsules provide a sustained release of the housed enzyme thus providing a therapeutic improvement in comparison to current therapies thus decreasing the need for repeated injections or high collagenase doses.

Stage of development

Cooperation stage dev stage: 
Field tested/evaluated

Partner sought

Cooperation area: 
They are looking for a company working on pharmaceutical or biotechnology sector. They should have the capacity to develop nanocapsule. The roll will be to adapt the nanocapsules to their needs and bring it to market, The Spanish groups are looking for license agreement, but if needed they could cooperate with the company in any further development.

Type and size

Cooperation task: 
SME 11-50,SME <10,SME 51-250,>500